* IDEC Pharmaceuticals Inc., of San Diego, said it will add at least$5 million in revenues in 1996 from the signing of deals in whichIDEC will apply its protein manufacturing and cell line developmentskills on a contract basis. Contract agreements were signed withMerck and Co. Inc., of Whitehouse Station, N.J.; OraVax Inc., ofCambridge, Mass.; and Pharmacia & Upjohn Inc., of Kalamazoo,Mich. Specific cell lines will be engineered for F. Hoffmann-LaRoche, of Basel, Switzerland, and Pharmacia & Upjohn.

* Lynx Therapeutics Inc., of Hayward, Calif., said Glaxo Wellcomeplc, of London, is terminating a licensing agreement signed in 1994by Lynx and The Wellcome Foundation, before Glaxo boughtWellcome. The agreement covered development of antisense drugs toprevent coronary artery restenosis following coronary angioplasty.The drug's safety was demonstrated in a 60-patient study inArgentina.

* Xoma Corp., of Berkeley, Calif., selected a lead compound andseveral alternates to move out of the research phase of its antifungaldevelopment program. The fungicidal compounds are peptides andpeptidomimetics derived from the company'sbactericidal/permeability increasing protein platform. The companyhopes to submit an investigational new drug application for the leadcompound, Mycoprex, by the end of 1996.

(c) 1997 American Health Consultants. All rights reserved.